Despite some recent improvements, millions of Americans still face significant barriers in affording GLP-1s. At the same time, many patients have found alternative, cheaper paths to get their hands on ...

Hailed by some as miracle drugs, GLP-1s have surged in popularity in the past few years. An estimated one out of every eight Americans is now on some version of them and scientists continue to ...

Some things are decidedly American: barbecue, Hollywood, and a lack of portion control. However, that last item is more than a stereotype. It’s a public health concern. Now, that story may be shifting ...

An experimental drug developed by Viking Therapeutics helped people maintain their weight loss even after stretching the doses to once a month or every other week. Viking’s stock VKTX closed 35.7% ...

GLP-1 medications carry a boxed warning about the potential increased risk of thyroid cancer in some people. However, current clinical evidence also points to significant GLP-1 cancer benefits. In ...

Roughly three-quarters of spending on GLP-1 drugs in Massachusetts was for weight loss in 2025, but spending in 2026 is expected to “drop significantly” due to changes in insurance coverage, according ...

Diabetes drugs have shown surprising benefits for the heart, kidneys, and brain. Now provocative animal research suggests they may influence the biology of aging itself. New evidence that semaglutide ...

More employers are putting GLP-1 coverage on the chopping block as they prepare for a historic year of healthcare cost hikes. New figures from the Business Group on Health (BGH) find that 14% of ...

Shaquille O’Neal has said a GLP-1-based medication helps him sleep better and feel more energetic after years of struggling with obstructive sleep apnea. Amy Schumer reported better energy, increased ...

If the first phase of the GLP-1 beauty boom was reactive, the next is likely to be defined by prevention, personalization, and products built around the changing body. “Ozempic face”, shorthand for ...

GLP-1 receptor agonists and dual agonists have transformed the treatment of obesity and other metabolic diseases, and a new editorial co-authored by Dr. Steven Heymsfield of LSU's Pennington ...

GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a new economic study finds. Researchers found that patients who used the drugs, sold under brand ...